Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis

This publication has 32 references indexed in Scilit:

• The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients
  European Journal Of Cancer, 2001
• Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study
  JNCI Journal of the National Cancer Institute, 1995
• Results of adjuvant interferon study In WHO melanoma programme
  The Lancet, 1994
• Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.
  The Journal of cell biology, 1993
• Groin dissection in malignant melanoma
  The American Journal of Surgery, 1986
• Natural Killer and Antibody-Dependent Cell-Mediated Cytotoxicity Activities and Large Granular Lymphocyte Frequencies in Viscum album-Treated Breast Cancer Patients
  Oncology, 1986
• Recombinant interferon-γ can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens
  European Journal of Immunology, 1985
• Stimulation of Humoral and Cellular Immunity by Viscum Preparations
  Planta Medica, 1982
• Tables of the number of patients required in clinical trials using the logrank test
  Statistics in Medicine, 1982
• Decline of natural non-selective cell-mediated cytotoxicity in patients with tumor progression
  Plastic and Reconstructive Surgery, 1977